CLASS ACTION UPDATE for HRTX, PVTL, RMED and ZUO: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

17-07-2019

NEW YORK, July 17, 2019 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court and further details about the cases can be found at the links provided. There is no cost or obligation to you.

Heron Therapeutics, Inc. (NASDAQ: HRTX)
Class Period:
October 31, 2018 - April 30, 2019
Lead Plaintiff Deadline: August 5, 2019
Join the action: https://www.zlk.com/pslra-1/heron-therapeutics-inc-loss-form?wire=3

About the lawsuit: Heron Therapeutics, Inc. allegedly made materially false and/or misleading statements during the class period and/or failed to disclose that: (i) Heron had failed to include adequate Chemistry, Manufacturing, and Controls (“CMC”) and non-clinical information in its NDA for HTX-011; (ii) the foregoing increased the likelihood that the FDA would not approve Heron’s NDA for HTX-011; and (iii) as a result, Heron’s public statements were materially false and misleading at all relevant times.

To learn more about the Heron Therapeutics, Inc. class action contact jlevi@levikorsinsky.com.

Pivotal Software, Inc. (NYSE: PVTL)
Class Period:
investors who purchased common stock pursuant or traceable to the April 2018 initial public offering and/or Pivotal securities between April 24, 2018 and June 4, 2019.
Lead Plaintiff Deadline: August 19, 2019
Join the action: https://www.zlk.com/pslra-1/pivotal-software-inc-loss-form?wire=3

About the lawsuit: Pivotal Software, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) Pivotal was facing major problems with its sales execution and a complex technology landscape; (ii) the foregoing headwinds resulted in deferred sales, lengthening sales cycles, and diminished growth as its customers and the industry’s sentiment shifted away from Pivotal’s principal products because the Company’s products were outdated, inadequate, and incompatible with the industry-standard platform; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.

To learn more about the Pivotal Software, Inc. class action contact jlevi@levikorsinsky.com.

Ra Medical Systems, Inc. (NYSE: RMED)
Class Period:
stockholders that purchased Ra Medical securities pursuant and/or traceable to the Company’s September 2018 initial public offering.
Lead Plaintiff Deadline: August 6, 2019
Join the action: https://www.zlk.com/pslra-1/ra-medical-systems-inc-loss-form?wire=3

About the lawsuit: Throughout the class period, Ra Medical Systems, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) the Company’s evaluation of sales personnel candidates was inadequate; (2) the Company’s training program for sales personnel was inadequate; (3) as a  result,  the  Company  could  not  reasonably  assure  that  its  newly  hired  sales  personnel  were  adequately  experienced;  (4) as  a  result,  the  Company  would  suffer a shortage of qualified sales personnel; (5) the Company’s manufacturing process  could  not  reasonably  support  increased  catheter  production;  (6) as  a  result, the Company would suffer production delays; and (7) as a result of the foregoing,   Defendants’   positive   statements   about   the   Company’s   business,   operations,  and  prospects,  were  materially  misleading  and/or  lacked  a  reasonable  basis.

To learn more about the Ra Medical Systems, Inc. class action contact jlevi@levikorsinsky.com.

Zuora, Inc. (NYSE: ZUO)
Class Period:
April 12, 2018 - May 30, 2019
Lead Plaintiff Deadline: August 13, 2019
Join the action: https://www.zlk.com/pslra-1/zuora-inc-loss-form?wire=3

About the lawsuit: During the class period, Zuora, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) the Company  would  focus  on  implementing  RevPro  for  new  customers  ahead  of  the  deadline  to  comply  with  accounting  standard  ASC  606;  (2)  as  a  result,  the  Company  lacked  adequate  resources  to  integrate  RevPro  with  the  core  business;  (3) the  Company  would  focus  on  RevPro integration a year after the acquisition closed; (4) delays in integrating RevPro would materially impact the business; (5)  the market for RevPro was limited to customers seeking to implement  new  accounting  standards  such  as  ASC  606;  (6)  after  the  deadline  for  ASC  606  compliance passed, demand for RevPro was reasonably likely to decline; and (7) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

To learn more about the Zuora, Inc. class action contact jlevi@levikorsinsky.com.

You have until the lead plaintiff deadlines to request the court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

250x148_zlk.jpg

Latest news
Related news
Related shares
Heron Therapeutics Inc
VOL 323,362
18.39 USD
0.39 / 2.17 %

Zuora
VOL 278,627
14.04 USD
0.23 / 1.67 %